Nutrigenetics

Nutrigenetics is an applied scientific discipline that studies how genetic variations in individuals—particularly Single Nucleotide Polymorphisms - SNPs—influence nutritional requirements, food metabolism, and physiological responses to diet. This discipline, which emerges from the integration of genetics, nutrition science, and omics technologies, forms the foundation for Personalized Nutrition and Precision Health approaches, replacing population-wide “one-size-fits-all” dietary recommendations with individualized strategies based on a person’s genotype.

History

Research into the genetic basis of nutritional requirements began in the mid-20th century with classical genetics. The term “nutrigenetics” was first used in the literature in 1975 by Richard Brennan to describe the role of genetic factors in the treatment of hypoglycemia. With the completion of the Human Genome Project in 2003 and the advancement of high-throughput genotyping technologies, the field has evolved into modern clinical and commercial applications.

Molecular Foundations and Metabolic Pathways

Nutrigenetics examines genetic variations in enzymes, transporters, and receptors that determine the fate of nutrients and bioactive compounds in the body—absorption, distribution, metabolism, and excretion. These variations alter the efficiency of metabolic pathways, thereby shaping individual nutritional needs and disease risks.

One-Carbon Metabolism and Methylation

This cycle, essential for DNA synthesis, repair, and epigenetic control of gene expression (methylation), depends on B vitamins (folate, B12, B6, B2) and is highly sensitive to genetic variations.

• Folate Cycle and MTHFR: The methylenetetrahydrofolate reductase (MTHFR) enzyme converts folate into its active form. The MTHFR 677C→T polymorphism can reduce enzyme activity by up to 70%, potentially disrupting DNA methylation processes and elevating homocysteine levels.
• Folate Trap and B12: Vitamin B12 deficiency or genetic defects in carrier proteins (Transcobalamin II) can trap folate in a metabolically unusable form. Variants in the methionine synthase (MTR) and methionine synthase reductase (MTRR) genes play a critical role in this cycle.
• Transsulfuration Pathway and CBS: The conversion of homocysteine to cysteine is mediated by the vitamin B6-dependent enzyme cystathionine beta-synthase (CBS). Variants in the CBS gene modulate cardiovascular risk by influencing vitamin B6 requirements and homocysteine levels.

Vitamin K Cycle

Vitamin K metabolism is one of the best-understood biochemical pathways illustrating gene-nutrient-drug interactions.

• VKORC1 and Gamma-Carboxylation: For vitamin K to activate clotting factors (Factors II, VII, IX, X), it must be reduced to its hydroquinone form. Polymorphisms in the gene encoding the vitamin K epoxide reductase (VKORC1) enzyme determine an individual’s vitamin K requirement.
• Pharmacogenetic Interaction: The anticoagulant warfarin exerts its effect by inhibiting the VKORC1 enzyme. An individual’s VKORC1 genotype and dietary vitamin K intake directly influence the therapeutic dose of warfarin. This is one of the strongest clinical examples of nutrigenetics.
• ApoE Effect: As a fat-soluble vitamin, vitamin K is transported in the blood via lipoproteins, particularly chylomicrons. The apolipoprotein E (ApoE) genotype affects the rate at which chylomicrons are cleared by the liver, thereby altering circulating vitamin K levels and its efficacy in bone health.

Lipid Metabolism and Nuclear Receptors

The processing of dietary fats and cholesterol homeostasis are controlled by a complex genetic network.

• ApoE Polymorphisms: The ApoE gene has three major alleles (E2, E3, E4). Carriers of the ApoE4 allele (“hyper-responders”) are more sensitive to dietary cholesterol and saturated fatty acids; in these individuals, saturated fat restriction is significantly more effective at lowering LDL cholesterol than in other genotypes.
• PPARs (Peroxisome Proliferator-Activated Receptors): These nuclear receptors (PPARG, PPARA) regulate gene expression involved in lipid metabolism when activated by fatty acids. Variants in the PPARG gene (e.g., Pro12Ala) influence insulin sensitivity to unsaturated fatty acids and the risk of Type 2 Diabetes.

Detoxification Phases and Bioactive Compounds

The body’s capacity to eliminate xenobiotics (drugs, toxins) and dietary components (caffeine, polyphenols) is genetically determined.

• Phase I Metabolism (CYP Enzymes): The cytochrome P450 1A2 (CYP1A2) enzyme metabolizes caffeine. Variants in the CYP1A2 gene classify individuals as “rapid” or “slow” metabolizers. In slow metabolizers, high coffee consumption increases the risk of hypertension and myocardial infarction; this risk is not observed in rapid metabolizers.
• Phase II Metabolism (GST Enzymes): Glutathione S-transferases (GSTs) play a role in combating oxidative stress and detoxifying carcinogens. Isothiocyanates found in cruciferous vegetables (broccoli, cabbage) induce these enzymes. Individuals with “null” (deleted/non-functional) variants of the GSTM1 or GSTT1 genes may derive less protective benefit from these vegetables or be more vulnerable to toxins.

Vitamin D and Bone Health

Vitamin D exerts its effects through the Vitamin D Receptor (VDR) in the cell nucleus. Polymorphisms in the VDR gene (FokI, BsmI, TaqI) affect an individual’s ability to utilize vitamin D, calcium absorption, and bone density. Individuals with these variants may require higher vitamin D doses than standard recommendations to manage osteoporosis risk.

Inflammation and Cytokines

Obesity and diabetes are underpinned by low-grade inflammation that is genetically modulated. Variants in the interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) genes alter an individual’s anti-inflammatory response to dietary omega-3 fatty acids. Individuals with high-risk genotypes have an increased need for omega-3 to reduce inflammation.

Taste Perception and Food Preference

Nutrigenetics influences not only metabolism but also what individuals choose to eat. Variants in the TAS1R2 (sweet taste) and TAS2R38 (bitter taste) genes determine individual susceptibility to sugary foods or bitter-tasting vegetables like broccoli. This genetic taste profile directly affects vegetable consumption habits and overall diet quality.

Energy Homeostasis and Appetite Control

• FTO and Hypothalamic Control: The FTO gene is active in hypothalamic pathways regulating energy balance and appetite (POMC/CART). The risk allele increases ghrelin (hunger hormone) levels and neuronal responses to high-calorie foods, contributing to obesity pathogenesis.
• Insulin Signaling (TCF7L2): TCF7L2 regulates insulin secretion in pancreatic beta cells and sensitivity to incretins (GLP-1). In carriers of variants in this gene, the glycemic load and fat composition of the diet (particularly the PUFA/SFA ratio) play a critical role in managing diabetes risk.

Nutrigenetic Testing and Application Methods

Nutrigenetic tests are tools that translate theoretical molecular knowledge into practical dietary recommendations.

Method: DNA, typically collected via non-invasive methods (buccal swab or saliva), is analyzed for specific SNPs validated by Genome-Wide Association Studies (GWAS) to be associated with nutritional responses.

Test Categories:

• Clinical Tests: Conducted under the supervision of a healthcare professional for managing a medical condition or assessing disease risk (e.g., familial hypercholesterolemia). Laboratory accreditation to ISO15189 standards is essential.
• Direct-to-Consumer (DTC) Tests: Commercial kits sold online and administered at home without professional guidance. These typically focus on “wellness,” “weight management,” or “vitamin needs.”

Reporting: Results are presented as personalized recommendations such as “caffeine sensitivity,” “lactose intolerance risk,” or “vitamin requirements.”

Ethical, Legal, and Social Issues

The commercialization and clinical translation of nutrigenetics have raised several ethical concerns:

• Direct-to-Consumer (DTC) Tests: Genetic tests sold online without healthcare professional oversight risk misinforming consumers. The majority of users (%98) take these tests out of curiosity but struggle to interpret the results.
• Marketing and Boundary Issues: Nutrigenetic companies frame genes as “non-deterministic but modifiable risk factors.” Ambiguity over whether these tests constitute “medical devices” or “lifestyle products” creates regulatory gaps.
• Laboratory Standards: Concerns exist regarding the quality of laboratories used by DTC test companies and their analytical validity. While Europe has established standards for medical genetic tests, tests marketed for “entertainment” or “lifestyle” purposes often fall outside these regulations.
• Economic Inequality: High test costs limit access to this technology to specific socioeconomic groups, exacerbating health disparities.

Clinical Application and Future

The integration of nutrigenetics into routine healthcare depends on developing standardized clinical protocols. In this context, international authorities have proposed the “Nutrigenomics Care Map,” which consists of four key stages: training healthcare professionals, assessing patient suitability, planning personalized interventions, and monitoring outcomes. However, the current lack of education among healthcare providers in interpreting complex genetic data remains the greatest barrier to widespread adoption of this model.

The future vision is shifting away from single-gene analyses toward a “Systems Biology” approach that views the organism as an integrated whole. This new model aims to combine genomic data with proteomic (protein), metabolomic (metabolite), and gut microbiome (gutome) analyses. Powered by artificial intelligence, this multi-omics approach will deliver far more precise nutritional strategies designed not only to prevent disease but to optimize overall health and wellness.

To strengthen the scientific credibility of the field, higher levels of evidence are essential. Beyond existing observational data, large-scale Randomized Controlled Trials (RCTs) are needed to definitively establish causality in gene-diet interactions. Obtaining such robust clinical evidence will elevate nutrigenetics from the realm of “probability” to “certainty,” enabling its inclusion in insurance reimbursement systems and its adoption as a standard component of clinical medicine.

Disclaimer: The content in this article is provided solely for general encyclopedic informational purposes. The information presented here should not be used for diagnosis, treatment, or medical advice. Always consult a physician or qualified healthcare professional before making decisions related to health. Neither the author nor the KÜRE Encyclopedia accepts any liability for consequences arising from the use of this information for diagnostic or therapeutic purposes.